<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neurology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30619057</article-id>
<article-id pub-id-type="pmc">6305538</article-id>
<article-id pub-id-type="doi">10.3389/fneur.2018.01100</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Yu-pei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/604169/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Bei-sha</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/630239/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Ji-feng</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/206717/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Center for Brain Disorders Research, Capital Medical University and Beijing Institute of Brain Disorders</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurology, Xiangya Hospital, Central South University</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Center for Medical Genetics, Central South University</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>
<aff id="aff5"><sup>5</sup><institution>Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Jiyan Ma, Van Andel Institute, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Jian Wang, Huashan Hospital Affiliated to Fudan University, China; Jennifer Steiner, Van Andel Institute, United States</p>
</fn>
<corresp id="c001">*Correspondence: Ji-feng Guo <email>guojifeng2003@163.com</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neurology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>1100</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>12</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Guo, Tang and Guo.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Guo, Tang and Guo</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Phospholipase A2 group VI (PLA2G6)-associated neurodegeneration (PLAN) includes a series of neurodegenerative diseases that result from the mutations in <italic>PLA2G6</italic>. PLAN has genetic and clinical heterogeneity, with different mutation sites, mutation types and ethnicities and its clinical phenotype is different. The clinical phenotypes and genotypes of PLAN are closely intertwined and vary widely. <italic>PLA2G6</italic> encodes a group of VIA calcium-independent phospholipase A2 proteins (iPLA<sub>2</sub>β), an enzyme involved in lipid metabolism. According to the age of onset and progressive clinical features, PLAN can be classified into the following subtypes: infantile neuroaxonal dystrophy (INAD), atypical neuroaxonal dystrophy (ANAD) and parkinsonian syndrome which contains adult onset dystonia parkinsonism (DP) and autosomal recessive early-onset parkinsonism (AREP). In this review, we present an overview of PLA2G6-associated neurodegeneration in the context of current research.</p>
</abstract>
<kwd-group>
<kwd>PLA2G6</kwd>
<kwd>iPLA<sub>2</sub>β</kwd>
<kwd>PLAN</kwd>
<kwd>INAD</kwd>
<kwd>ANAD</kwd>
<kwd>DP</kwd>
<kwd>AREP</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="96"></ref-count>
<page-count count="9"></page-count>
<word-count count="6806"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>PLA2G6-associated neurodegeneration (PLAN) is a complex group of neurodegenerative diseases that result from mutations in a gene known as <italic>PLA2G6</italic>. According to the age of onset and clinical features, PLAN can be mainly classified into four subtypes: infantile neuroaxonal dystrophy (INAD), atypical neuroaxonal dystrophy (ANAD), adult-onset dystonia-parkinsonism (DP) and autosomal recessive early-onset parkinsonism (AREP). The onset of INAD and ANAD occurs in childhood and these diseases manifest as progressive psychomotor deterioration, axial dystonia, spasticity, and ataxia, as well as optic atrophy in some children. Cerebellar cortical atrophy and iron deposition in the globus pallidus and substantia nigra can be detected by Magnetic Resonance Imaging (MRI) in most patients (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Past research has suggested that PLAN can be classified as neurodegeneration with brain iron accumulation II (NBIA II) (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). However, although there is a phenotypical intersection between NBIA and PLAN, we propose that neither disease can completely include the other. The onset of DP and AREP occurs in adulthood and patients often have normal birth, achieve early age mile-stones and have a normal childhood. Patients with DP or AREP show clinical manifestations of parkinsonian syndrome. These patients are characterized by bradykinesia and tremors with occurrence of dystonia, in addition to cognitive regression as well as gait instability. Some symptoms are similar to those of parkinsonism, but cerebellar cortical atrophy and iron deposition do not occur in these patients. A high clinical variability is exhibited in these phenotypes, but age of onset and clinical manifestations are the main criteria used to make distinctions between the subtypes of PLAN.</p>
<p>In 2006, the <italic>PLA2G6</italic> gene was initially cloned in two unrelated Israeli INAD families, both of which included consanguineous marriages (<xref ref-type="bibr" rid="B5">5</xref>). In 2010, for the first time, the <italic>PLA2G6</italic> gene mutation was associated with parkinsonism (<xref ref-type="bibr" rid="B6">6</xref>). At present, the pathogenesis of the <italic>PLA2G6</italic> mutation in neurodegenerative diseases remains unclear. Different mutations and even mutations at the same site may cause phenotypic disparities. For example, the presence of pathogenic <italic>PLA2G6</italic> gene mutation sites (p. D331Y) reported in AREP patients can be associated with a 70% decrease in enzyme activity (<xref ref-type="bibr" rid="B7">7</xref>), and the (His597fx69) frameshift mutation can cause the activity of enzymes to differ from previous cases (<xref ref-type="bibr" rid="B8">8</xref>). Here, we speculate whether different mutations can result in the diversity of enzymatic activity, thus causing different clinical phenotypes. In this review, we demonstrate clinical phenotypes with different genotypes in PLAN and discuss the underlying relationships of these symptoms with evidence from genetic studies, with a primary focus on the clinical manifestations and genotypic features supported by neuropsychology research, neuroimaging and molecular genetics. Finally, we explore the link between phenotypes and genotypes for PLAN in the light of current <italic>PLA2G6</italic> gene research.</p>
</sec>
<sec id="s2">
<title>The Clinical Phenotypes Of PLA2G6-Associated Neurodegeneration</title>
<p>The most common phenotype of the <italic>PLA2G6</italic> gene mutation is NBIA II. PLAN mainly includes INAD, ANAD, and two other diseases are present in parkinsonian syndrome, DP and AREP (<xref ref-type="bibr" rid="B9">9</xref>). In addition, some patients present sporadic parkinsonism similar to AREP, known as sporadic early-onset parkinsonism (EOP) (<xref ref-type="bibr" rid="B10">10</xref>). <italic>PLA2G6</italic> mutations that cause phenotypical clinical characteristics are shown in Table <xref ref-type="table" rid="T1">1</xref>. Moreover, these mutations are associated with hypothyroidism, schizophrenia, diabetes and other diseases (<xref ref-type="bibr" rid="B11">11</xref>–<xref ref-type="bibr" rid="B13">13</xref>). On magnetic resonance images, most patients carrying the <italic>PLA2G6</italic> mutation showed an iron accumulation in the globus pallidus and/or the substantia nigra in T2-weighted images (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). In pathological examinations of individuals with the <italic>PLA2G6</italic> mutation, abnormal α-synuclein proteins and hyperphosphorylation of tau proteins were found, and may progress to become Lewy bodies (LBs), neurofibrillary tangles and neuropil threads (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Neuronal biopsies of patients' central nervous systems and peripheral nervous systems tissue provided evidence of the presence of axonal distension, swellings and spheroid bodies (<xref ref-type="bibr" rid="B17">17</xref>). In other cases, brain tissue sections with Perl's staining showed iron deposition in the globus pallidus or substantia nigra (<xref ref-type="bibr" rid="B18">18</xref>), and oculogyric crises were also found in PLAN patients (<xref ref-type="bibr" rid="B19">19</xref>). Here, we describe the clinical features of several PLA2G6-associated neurodegenerative diseases.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Summary of the clinical features in the PLA2G6-associated neurodegeneration.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>INAD</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>ANAD</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>DP</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>AREP</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Age of onset</td>
<td align="left" colspan="1" rowspan="1" valign="top">6 months to 3-year-old</td>
<td align="left" colspan="1" rowspan="1" valign="top">Early childhood to juvenescent phase</td>
<td align="left" colspan="1" rowspan="1" valign="top">20-40 years old</td>
<td align="left" colspan="1" rowspan="1" valign="top">Below 40 years old</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Progression</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rapid</td>
<td align="left" colspan="1" rowspan="1" valign="top">Slower than INAD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Slow</td>
<td align="left" colspan="1" rowspan="1" valign="top">Slow</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Initial symptoms</td>
<td align="left" colspan="1" rowspan="1" valign="top">Psychomotor deterioration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cerebellar ataxia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Parkinsonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Parkinsonism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Main clinical symptoms</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tetraparesis, truncal hypotonia, limbo dystonia, mental deterioration, cerebellar ataxia, spasticity, optic atrophy, epilepsy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Psychomotor regression, seizure, gait instability, autism, dystonia, dysarthria, eye movement abnormalities, epilepsy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bradykinesia, tremor, dystonia, gait instability, rigidity, cognitive deterioration, psychiatric symptoms</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bradykinesia, rigidity, tremor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Important signs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cerebellar ataxia, hypotonia,hyporeflexia, nystagmus, strabismus</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cerebellar ataxia, hypermyotonia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypermyotonia, extrapyramidal signs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypermyotonia (especially in lower limbs)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain MRI/image signs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Brain iron accumulation in the two sides of globus pallidus and substantia nigra, cerebellar atrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Brain iron accumulation in the two sides of basal ganglia, cerebellar atrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">A substantial reduction in dat</td>
<td align="left" colspan="1" rowspan="1" valign="top">A substantial reduction in dat</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">EEG</td>
<td align="left" colspan="1" rowspan="1" valign="top">Generalized fast rhythms</td>
<td align="left" colspan="1" rowspan="1" valign="top">Abnormal rhythms</td>
<td align="left" colspan="1" rowspan="1" valign="top">None</td>
<td align="left" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pathology</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neuroaxonal swellings and spheroid bodies, Lewy body, hyperphosphorylated-tau</td>
<td align="left" colspan="1" rowspan="1" valign="top">The loss of Purkinje cell in cerebellum, hyperphospholipase-tau, Lewy body</td>
<td align="left" colspan="1" rowspan="1" valign="top">None</td>
<td align="left" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lifetime</td>
<td align="left" colspan="1" rowspan="1" valign="top">Short</td>
<td align="left" colspan="1" rowspan="1" valign="top">Longer than INAD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Longer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Longer</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Treatment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Symptomatic treatment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Symptomatic treatment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dopaminergic agents</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dopaminergic agents</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Clinical features of the PLAN presented in this review</italic>.</p>
<p><italic>INAD, Infantile neuroaxonal dystrophy; ANAD, Atypical neuroaxonal dystrophy; DP, adult-onset dystonia-parkinsonism; AREP, autosomal recessive early-onset parkinsonism; EEG, electroencephalogram; DAT, dopamine transporter</italic>.</p>
</table-wrap-foot>
</table-wrap>
<sec>
<title>Infantile Neuroaxonal Dystrophy (INAD)</title>
<p>INAD was first discovered and described by Seitelberger in 1952, and was initially known as Seitelberger's disease (<xref ref-type="bibr" rid="B20">20</xref>). INAD is an autosomal recessive neurodegenerative disease (<xref ref-type="bibr" rid="B20">20</xref>). The age of onset is around 2 years old, mostly occurring before the age of 18 (<xref ref-type="bibr" rid="B21">21</xref>). Before the onset of the disease, compared to normal infants, some patients may present a delay in psychomotor development, while most cases present no indication (<xref ref-type="bibr" rid="B22">22</xref>). This rare neurological disease is mainly characterized by progressive psychomotor deterioration, truncal hypotonia, cerebellar ataxia, extrapyramidal signs, and early visual failure caused by optic atrophy. Generalized fast rhythms are frequently observed in electroencephalogram (EEG) and seizures may also occur (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B23">23</xref>–<xref ref-type="bibr" rid="B25">25</xref>). Patients often show slight psychomotor and dystonia disorders during infancy and childhood. The other clinical manifestations are bilateral limb spasticity, bulbar signs (impaired swallowing and dyspnoea), pendular nystagmus, strabismus, distal contractures, optic atrophy, and hearing impairment (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B26">26</xref>–<xref ref-type="bibr" rid="B30">30</xref>). Cognitive impairment might also be observed in the disease evaluations. In most INAD cases, an MRI shows signs of iron accumulation in the globus pallidus and/or the substantia nigra (<xref ref-type="bibr" rid="B21">21</xref>). At the early stages of the disease, the MRI might not detect the iron accumulation, but as the disease progresses, iron accumulation can often be detected by the MRI between the ages of 3 and 25 years old (<xref ref-type="bibr" rid="B18">18</xref>). Another typical sign of INAD is a fast progression of cerebellar atrophy, which is shown by the MRI (<xref ref-type="bibr" rid="B31">31</xref>). In addition, some MRIs also show thin optic chiasma, signal hyperintensity of the dentate nuclei and white matter, and cerebral cortical atrophy (<xref ref-type="bibr" rid="B32">32</xref>). An electromyography (EMG) also shows denervation in the peripheral nervous system (<xref ref-type="bibr" rid="B29">29</xref>), and an EEG can reveal the widespread high-amplitude fast activity at 16–22 Hz after 2 years of age (<xref ref-type="bibr" rid="B33">33</xref>). Visual evoked potentials (VEPs) and electroretinograms (ERGs) appear normal in the early stage of the disease, followed by an increase in abnormal signs over time (<xref ref-type="bibr" rid="B27">27</xref>). In a Chinese population, axonal spheroids were discovered in the biopsy specimens of skin and sural nerves among ten patients with INAD (<xref ref-type="bibr" rid="B34">34</xref>). In addition, neuroimaging showed cerebellar atrophy occurring in the early stages of INAD, but not in other late-onset diseases. Most patients with INAD have progressively worsening symptoms throughout infancy and early childhood and have a shorter survival period (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B34">34</xref>). The main features of the pathology are axon spheroids and vacuoles, which are widely present in the central and peripheral nervous systems. Brain tissue pathology can also reveal the presence of iron deposits in the bilateral basal ganglia and globus pallidus (<xref ref-type="bibr" rid="B35">35</xref>), as well as phosphorylated α-synuclein-positive LBs. Phosphorylated tau-positive neurofibrillary tangles can also be found in some cases (<xref ref-type="bibr" rid="B16">16</xref>). Currently, there are no effective treatments, only palliative methods that can relieve symptoms and prevent secondary complications.</p>
</sec>
<sec>
<title>Atypical Neuroaxonal Dystrophy (ANAD)</title>
<p>ANAD is another subtype of PLAN, with atypical clinical characteristics. When the onset of the <italic>PLA2G6</italic> mutation occurs later, the phenotype may be atypical. Different from INAD, the age of onset for ANAD ranges from 3 years old to the late teens. Before the onset of clinical symptoms, motor and intelligence development is relatively normal in these patients (<xref ref-type="bibr" rid="B16">16</xref>). Patient symptoms include ataxia, rigidity, spasticity, dystonia, and even myoclonic epilepsy. ANAD is also associated with mental impairment and often visual failure. Some patients develop symptoms before 3 years of age, similar to classical INAD, but neurological deterioration during the course of the disease is often delayed (<xref ref-type="bibr" rid="B26">26</xref>). In some cases, an MRI can reveal advanced cerebellar atrophy and iron accumulation in the substantia nigra (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B21">21</xref>), albeit the absence of cerebellar ataxia (<xref ref-type="bibr" rid="B36">36</xref>). Iron deposits in the substantia nigra are present in some atypical cases (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B21">21</xref>), but it is not a universal feature of PLAN. The majority of late-onset cases lack signs of iron accumulation, and MRIs may even appear completely normal. Other cases may show cortical atrophy or white matter changes; for instance, in one study, obvious cerebellar atrophy was detected during head imaging examination and the bilateral basal ganglia showed signs of iron deposition (<xref ref-type="bibr" rid="B2">2</xref>). Pathological examination also revealed the loss of the cerebellar Purkinje cells, the deposition of highly phosphorylated tau proteins that formed neurofibrillary tangles and the deposition of phosphorylated α-synuclein that formed LBs (<xref ref-type="bibr" rid="B16">16</xref>). Compared to patients with INAD, patients with ANAD present a slower progression and longer survival times (<xref ref-type="bibr" rid="B37">37</xref>). The treatment of ANAD is similar to that of INAD.</p>
</sec>
</sec>
<sec id="s3">
<title>Parkinsonian Syndrome In Plan</title>
<sec>
<title>Adult-Onset Dystonia-Parkinsonism (DP)</title>
<p>From the perspective of onset age, DP differs from INAD or ANAD, with a much later onset, occurring from 20 to 40 years old, and exhibiting some typical symptoms, including marked cognitive impairment and some parkinsonian manifestations, such as bradykinesia, ataxia, limb tremors, dystonia, dysarthria, and epilepsy (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). Moreover, oculogyric crises are induced by levodopa in some cases (<xref ref-type="bibr" rid="B40">40</xref>). In addition to motor disturbances, non-motor symptoms, such as depression and other adolescent-like behavior changes are observed in DP (<xref ref-type="bibr" rid="B41">41</xref>). An MRI of patients with DP reveals some abnormal signals from the frontal lobe, corresponding to severe cognitive impairment. Compared with the MRI results observed in patients with INAD, the MRI results of patients with DP exhibit a rate and degree of severity of iron accumulation and cerebellum atrophy, indicating that these features play a minor role in the manifestation of DP (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B42">42</xref>). The disease progresses rapidly in patients and is effectively treated with levodopa or polyamine receptor agonists. Patients will often temporarily have dyskinesia after treatment with dopa preparations (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B43">43</xref>).</p>
</sec>
<sec>
<title>Autosomal Recessive Early-Onset Parkinsonism (AREP)</title>
<p>Based on our previous study, the <italic>PLA2G6</italic> gene was confirmed to be associated with AREP (<xref ref-type="bibr" rid="B7">7</xref>). Patients with <italic>PLA2G6</italic>-related AREP exhibited tremors and bradykinesia in the lower limbs, postural instability and hypomimia. Additionally, cerebellar ataxia and autonomic dysfunction were recognized in the late stages of the disease. In the MRI, no evidence of iron deposition was found on T2-weighted images. Levodopa treatment can also be beneficial to AREP patients. In recent years, the <italic>PLA2G6</italic> mutation was found to be closely related to sporadic early-onset parkinsonism (EOP) (<xref ref-type="bibr" rid="B6">6</xref>). Unlike AREP, the genetic characterization of EOP is sporadic. The age of onset of EOP is around 20 years old. The disease is characterized by extrapyramidal signs, cognitive decline, dystonia, dysarthria/dysphonia, swallowing problems, limb tremors and abnormal gait, which are sensitive to dopaminergic agents. The MRIs of EOP patients may show iron accumulations in the brain but not in all individuals; frontal lobe and general white matter atrophy can also be observed (<xref ref-type="bibr" rid="B44">44</xref>). EEG and EMG examinations are normal in some individuals. Epileptic seizures also occur during the progression of the disease. Currently, some researchers believe that the <italic>PLA2G6</italic> mutation is not a major risk factor for Parkinson's disease in Asian populations (<xref ref-type="bibr" rid="B45">45</xref>–<xref ref-type="bibr" rid="B47">47</xref>). Moreover, patients with EOP are sensitive to dopamine treatment.</p>
<p>In addition to DP and AREP, there is also a new view regarding the link between PLAN and hereditary spastic paraplegia (HSP). Reports from different countries show that some clinical symptoms of patients with PLAN do not solely include those related to parkinsonian syndrome (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>). The clinical features of these patients are mental retardation, extrapyramidal symptoms, lower limb spasticity, cerebellar ataxia, and peripheral neuropathy. Thin corpus callosa and iron accumulations can also be found on MRI images (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B50">50</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>The Genotypes Of PLA2G6—Associated Neurodegeneration</title>
<p><italic>PLA2G6</italic> mutations have both clinical and genetic heterogeneity. Patients have different types of <italic>PLA2G6</italic> mutations, including missense mutations, truncation mutations, and copy number variations. Individuals carrying the <italic>PLA2G6</italic> mutation can also have different clinical phenotypes depending on specific genotypic features. The previous reported mutation sites of <italic>PLA2G6</italic> are listed in Figure <xref ref-type="fig" rid="F1">1</xref> (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B6">6</xref>–<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B15">15</xref>–<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B41">41</xref>–<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B51">51</xref>–<xref ref-type="bibr" rid="B69">69</xref>). Reportedly, in two <italic>PLA2G6</italic> mutation families, all three patients carried <italic>PLA2G6</italic> mutations (p.R632W) but presented different clinical manifestations than previously reported (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B43">43</xref>). Shi et al. (<xref ref-type="bibr" rid="B7">7</xref>) also suggested that the incomplete loss of enzymatic activity causes AREP. Moreover, expansive copy number variants (CNVs) have been detected in the development of PLAN (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B57">57</xref>). The crystal structure of iPLA<sub>2</sub>β is complex, and the different mutation sites are disparately located on the enzyme (<xref ref-type="bibr" rid="B70">70</xref>). According to previous studies, mutation sites in the ankyrin repeat (AR) domains, catalytic(CAT) domains, or any other domains may lead to different enzyme activities. We speculate that the coincident mutation of PLAN may initiate the pathological mechanisms. The pivotal factor that affects the relationships between mutations and clinical phenotypes may be enzyme activity. However, more cases are needed to clarify the relationships between genotypes and phenotypes of <italic>PLA2G6</italic>.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Identified mutation sites of <italic>PLA2G6</italic> gene. <bold>(A)</bold> There are 17 exons of the <italic>PLA2G6</italic> gene, and mutation sites were distributed on the exons. <bold>(B)</bold> Schematic representation in scale of the full-length iPLA2β protein with functional regions and position of the variant protein. The mutations which cause dystonia-parkinsonism, previously identified by others, are shown above. 1–7 = ankyrin repeat region. The position of calmodulin domains and motifs was provided by <ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/uniprot/O60733">https://www.uniprot.org/uniprot/O60733</ext-link>. Red, INAD; Blue, ANAD; Green, DP; Yellow, NBIA; Purple, parkinsonian syndrome.</p>
</caption>
<graphic xlink:href="fneur-09-01100-g0001"></graphic>
</fig>
</sec>
<sec id="s5">
<title>Genetic Function Of <italic>PLA2G6</italic></title>
<p>The <italic>PLA2G6</italic> gene is located on 22q13.11 (<xref ref-type="bibr" rid="B71">71</xref>), with 17 exons. The protein, encoded by <italic>PLA2G6</italic>, is a member of the A<sub>2</sub> phospholipase family (PLA<sub>2</sub>), known as group VI calcium-independent phospholipase A<sub>2</sub> (iPLA<sub>2</sub>β). It is an enzyme functioning in inflammation, immune responses, cell proliferation, apoptosis and remodeling of membrane phospholipids (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B72">72</xref>).</p>
<p>iPLA<sub>2</sub>β is an intracellular and calcium ion-independent protein. This protein was first isolated from the P388D1 cell line and described in 1994 (<xref ref-type="bibr" rid="B73">73</xref>). iPLA<sub>2</sub>β contains 806 amino acids; human iPLA<sub>2</sub>β is 88 KDa and contains an N-terminal domain, ARs domain and CAT domains (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B75">75</xref>). The iPLA<sub>2</sub>β protein encoded by the <italic>PLA2G6</italic> gene is an important lipase in the human body which is widely distributed in the tissues of human organs (<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org">http://www.proteinatlas.org</ext-link>). In the human brain, iPLA<sub>2</sub>β is highly expressed in the substantia nigra, cortex and the hippocampus (<xref ref-type="bibr" rid="B76">76</xref>–<xref ref-type="bibr" rid="B78">78</xref>). iPLA<sub>2</sub>β can hydrolyse the sn-2 acyl chain of phospholipids and the major decomposition products are docosahexaenoic acid (DHA) and lysophospholipids (<xref ref-type="bibr" rid="B75">75</xref>). Under the action of cyclooxygenase and lipoxygenase, DHA produces neuroprotectin D1 (NPD1), and NPD1 plays a crucial role in anti-inflammatory processes and immune responses in the brain (<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B80">80</xref>). NPD1 is specifically involved in the catabolism of fatty acids and arachidonic acid (AA)-related inflammatory reactions (<xref ref-type="bibr" rid="B81">81</xref>, <xref ref-type="bibr" rid="B82">82</xref>). iPLA<sub>2</sub>β exerts an anti-inflammatory function through the action of NPD1, against AA, and has a protective effect on cells in inflammatory reactions. The loss of iPLA<sub>2</sub>β's function may affect proteins and processes normally involved in regulating the movement of membranes within axons and dendrites, subsequently leading to mitochondrial abnormalities and synaptic transmission impairment (<xref ref-type="bibr" rid="B83">83</xref>–<xref ref-type="bibr" rid="B86">86</xref>). Moreover, animal models of PLA2G6 showed neurodegeneration (<xref ref-type="bibr" rid="B87">87</xref>) and revealed that iPLA<sub>2</sub>β is closely related to dopaminergic cells, axonal development (<xref ref-type="bibr" rid="B88">88</xref>), endoplasmic reticulum stress, mitophagy impairment (<xref ref-type="bibr" rid="B89">89</xref>), and changes in Ca(2+) signaling (<xref ref-type="bibr" rid="B90">90</xref>). Thus, these animals provide great disease models for PLAN.</p>
<p>iPLA<sub>2</sub>β is associated with a variety of diseases and medical emergencies, including strokes, spinal cord injuries and neurodegenerative diseases (<xref ref-type="bibr" rid="B91">91</xref>–<xref ref-type="bibr" rid="B93">93</xref>). However, the pathogenesis of <italic>PLA2G6</italic> in neurodegenerative diseases remains unclear and the function of iPLA<sub>2</sub>β, resulting from different mutation sites and types, may be the vital factor. It was reported that pathogenic <italic>PLA2G6</italic> gene mutation sites (p.A341T, p.G517C) in patients with INAD\NBIA can cause significant decreases in enzymatic activity (<xref ref-type="bibr" rid="B94">94</xref>). Moreover, the activity of iPLA2β was reduced by 70% compared to normal functioning, owing to the p.D331Y homozygous mutation (<xref ref-type="bibr" rid="B7">7</xref>) and the (His597fx69) frameshift mutation, making the activity of enzymes &lt;6% compared to that of WT iPLA<sub>2</sub>β (<xref ref-type="bibr" rid="B8">8</xref>). Differential enzymatic activity caused by multifarious mutations may be a key factor in explaining the high clinical variability in PLAN.</p>
</sec>
<sec id="s6" sec-type="conclusions">
<title>Conclusion</title>
<p><italic>PLA2G6</italic> mutations have both genotypic and phenotypic heterogeneity. Here, we summarized the major subtypes of PLAN and analyzed their potential relationships. Mutated forms of <italic>PLA2G6</italic> include missense mutations, truncated mutants, fragment deletions, and CNVs. Individuals carrying different <italic>PLA2G6</italic> mutations may also display varied clinical symptoms. The subtypes of <italic>PLA2G6</italic> mutation-related disorders are INAD, ANAD, DP, and AREP, with distinct characteristics associated with each disorder. In recent years, HSP has also been found to be associated with the <italic>PLA2G6</italic> gene mutations. Some mutation sites of HSP also coincide with the mutation sites of the previous four phenotypes. Whether HSP can be considered a PLAN phenotype requires additional research. In the cases of INAD/ANAD, an MRI exhibited iron accumulation in the basal ganglia and globus pallidus, as well as abnormal α-synuclein and hyperphosphorylation of tau proteins in brain tissues, while other cases had relatively moderate MRI features. Moreover, α-synuclein and neurofibrillary tangles pathologies indicate that PLAN may be consistent with idiopathic Parkinson's disease (iPD) to some extent. Interestingly, the view that later onset cases tend to have less tau involvement but still severe α-synuclein pathology may need further discussion. (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B95">95</xref>).</p>
<p>The link between the phenotypes and genotypes of PLAN suggests that different mutation sites lead to various protein activities. Mutation sites in different domains, for example, ARs or the CAT domains, may have different effects to physiological processes. Based on a previously described case, a <italic>PLA2G6</italic> gene mutation site can result in patients presenting several different phenotypes. Potentially, enzyme activity as well as DNA methylation, synergistic genetic processes, or environmental factors may participate in the pathogenesis of PLAN. Based on the information presented in Figure <xref ref-type="fig" rid="F1">1</xref>, we speculate that there is no obvious rule for mutation site distribution of PLAN, but further studies are required to clarify why there is no mutation localized in exon 9 and whether the mutations can be categorized according to the 3D structure of iPLA<sub>2</sub>β (<xref ref-type="bibr" rid="B70">70</xref>).</p>
<p>In recent decades, the study on <italic>PLA2G6</italic>-related disorders has been performed in terms of pathogenesis and iPLA<sub>2</sub>β function, which provides hope of a detailed understanding of this disease. iPLA<sub>2</sub>β is a vital protein involved in immune responses, inflammatory processes, fatty acid metabolism, oxidative stress, and apoptosis, which may be the pathogenic mechanisms underlying the progression of neurodegenerative diseases. iPLA<sub>2</sub>β is involved in the metabolism of DHA and NPD1, which are closely related to human neurocognitive development and anti-inflammatory properties, respectively (<xref ref-type="bibr" rid="B96">96</xref>). Whether mental retardation manifesting in young children is caused as a result of iPLA<sub>2</sub>β affecting the metabolism of DHA is unclear; a better understanding would perhaps provide new information regarding the treatment of PLAN. In addition, iron metabolism may offer clues regarding disease therapy. In summary, the features of PLAN may provide information regarding the etiology of other neurodegenerative diseases.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>YG conceived the study and wrote the manuscript. BT and JG discussed and revised the manuscript. YG prepared the tables. All authors read and approved the final version of the manuscript.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by grant 2016YFC1306000 from the National Key Plan for Scientific Research and Development of China (to BT), grant 2017YFC0909100 from the National Key Plan for Scientific Research and Development of China (to JG), grants 81371405 and 81873785 from the National Natural Science Foundation of China (to JG), and grant 2017JJ1037 from Hunan Science Funds for Distinguished Young Scholar (to JG).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>A</given-names></name><name><surname>Westaway</surname><given-names>SK</given-names></name><name><surname>Holm</surname><given-names>IE</given-names></name><name><surname>Kotzbauer</surname><given-names>PT</given-names></name><name><surname>Hogarth</surname><given-names>P</given-names></name><name><surname>Sonek</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Neurodegeneration associated with genetic defects in phospholipase A(2)</article-title>. <source/>Neurology (<year>2008</year>) <volume>71</volume>:<fpage>1402</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000327094.67726.28</pub-id><pub-id pub-id-type="pmid">18799783</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurian</surname><given-names>MA</given-names></name><name><surname>Morgan</surname><given-names>NV</given-names></name><name><surname>Macpherson</surname><given-names>L</given-names></name><name><surname>Foster</surname><given-names>K</given-names></name><name><surname>Peake</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN)</article-title>. <source/>Neurology (<year>2008</year>) <volume>70</volume>:<fpage>1623</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000310986.48286.8e</pub-id><pub-id pub-id-type="pmid">18443314</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>SA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Bhatia</surname><given-names>KP</given-names></name></person-group>. <article-title>Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations</article-title>. <source/>Mov Disord. (<year>2012</year>) <volume>27</volume>:<fpage>42</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/mds.23971</pub-id><pub-id pub-id-type="pmid">22031173</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayflick</surname><given-names>SJ</given-names></name><name><surname>Kurian</surname><given-names>MA</given-names></name><name><surname>Hogarth</surname><given-names>P</given-names></name></person-group>. <article-title>Neurodegeneration with brain iron accumulation</article-title>. <source/>Handb Clin Neurol. (<year>2018</year>) <volume>147</volume>:<fpage>293</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-444-63233-3.00019-1</pub-id><pub-id pub-id-type="pmid">29325618</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khateeb</surname><given-names>S</given-names></name><name><surname>Flusser</surname><given-names>H</given-names></name><name><surname>Ofir</surname><given-names>R</given-names></name><name><surname>Shelef</surname><given-names>I</given-names></name><name><surname>Narkis</surname><given-names>G</given-names></name><name><surname>Vardi</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>PLA2G6 mutation underlies infantile neuroaxonal dystrophy</article-title>. <source/>Am J Hum Genet. (<year>2006</year>) <volume>79</volume>:<fpage>942</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1086/508572</pub-id><pub-id pub-id-type="pmid">17033970</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name><name><surname>Guevara</surname><given-names>R</given-names></name><name><surname>Federoff</surname><given-names>M</given-names></name><name><surname>Hanagasi</surname><given-names>H</given-names></name><name><surname>Sina</surname><given-names>F</given-names></name><name><surname>Elahi</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations</article-title>. <source/>Mov Disord. (<year>2010</year>) <volume>25</volume>:<fpage>1791</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1002/mds.23221</pub-id><pub-id pub-id-type="pmid">20669327</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>CH</given-names></name><name><surname>Tang</surname><given-names>BS</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>ZY</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>LZ</given-names></name><etal></etal></person-group>. <article-title>PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort</article-title>. <source/>Neurology (<year>2011</year>) <volume>77</volume>:<fpage>75</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e318221acd3</pub-id><pub-id pub-id-type="pmid">21700586</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>YX</given-names></name><name><surname>Xu</surname><given-names>ZP</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>HM</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Hu</surname><given-names>XY</given-names></name></person-group>. <article-title>Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease</article-title>. <source/>Parkins Relat Disord. (<year>2013</year>) <volume>19</volume>:<fpage>21</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2012.07.016</pub-id><pub-id pub-id-type="pmid">23182313</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>A</given-names></name><name><surname>Kurian</surname><given-names>MA</given-names></name><name><surname>Maher</surname><given-names>ER</given-names></name><name><surname>Hogarth</surname><given-names>P</given-names></name><name><surname>Hayflick</surname><given-names>SJ</given-names></name></person-group>
<article-title>PLA2G6-Associated Neurodegeneration</article-title>. In: <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Bean</surname><given-names>LJH</given-names></name><name><surname>Stephens</surname><given-names>K</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name></person-group>, editors. <source/>GeneReviews®.
<publisher-loc>Seattle WA</publisher-loc>: <publisher-name>University of Washington</publisher-name> (<year>1993</year>).</mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Cen</surname><given-names>Z</given-names></name><name><surname>Ouyang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name></person-group>. <article-title>Homozygous p.D331Y mutation in PLA2G6 in two patients with pure autosomal-recessive early-onset parkinsonism: further evidence of a fourth phenotype of PLA2G6-associated neurodegeneration</article-title>. <source/>Parkinsonism Relat Disord. (<year>2015</year>) <volume>21</volume>:<fpage>420</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.01.012</pub-id><pub-id pub-id-type="pmid">25660576</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalheiser</surname><given-names>NR</given-names></name><name><surname>Swanson</surname><given-names>DR</given-names></name></person-group>. <article-title>Calcium-independent phospholipase A2 and schizophrenia</article-title>. <source/>Arch Gen Psychiatry (<year>1998</year>) <volume>55</volume>:<fpage>752</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="pmid">9707387</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanadham</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Crankshaw</surname><given-names>M</given-names></name><name><surname>Grant</surname><given-names>GA</given-names></name><etal></etal></person-group>
<article-title>Pancreatic islets and insulinoma cells express a novel isoform of group VIA phospholipase A2 (iPLA2 beta) that participates in glucose-stimulated insulin secretion and is not produced by alternate splicing of the iPLA2 beta transcript</article-title>. <source/>Biochemistry (<year>2003</year>) <volume>42</volume>:<fpage>13929</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1021/bi034843p</pub-id><pub-id pub-id-type="pmid">14636061</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>NV</given-names></name><name><surname>Westaway</surname><given-names>SK</given-names></name><name><surname>Morton</surname><given-names>JE</given-names></name><name><surname>Gregory</surname><given-names>A</given-names></name><name><surname>Gissen</surname><given-names>P</given-names></name><name><surname>Sonek</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron</article-title>. <source/>Nat Genet. (<year>2006</year>) <volume>38</volume>:<fpage>752</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/ng1826</pub-id><pub-id pub-id-type="pmid">16783378</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>AO</given-names></name><name><surname>Aldrees</surname><given-names>A</given-names></name><name><surname>Elmalik</surname><given-names>SA</given-names></name><name><surname>Hassan</surname><given-names>HH</given-names></name><name><surname>Michel</surname><given-names>M</given-names></name><name><surname>Stevanin</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Ophthalmic features of PLA2G6-related paediatric neurodegeneration with brain iron accumulation</article-title>. <source/>Br J Ophthalmol. (<year>2014</year>) <volume>98</volume>:<fpage>889</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1136/bjophthalmol-2013-304527</pub-id><pub-id pub-id-type="pmid">24522175</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>SA</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Kidd</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations</article-title>. <source/>Neurobiol Aging (<year>2012</year>) <volume>33</volume>:<fpage>814</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.05.009</pub-id><pub-id pub-id-type="pmid">20619503</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riku</surname><given-names>Y</given-names></name><name><surname>Ikeuchi</surname><given-names>T</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Mimuro</surname><given-names>M</given-names></name><name><surname>Mano</surname><given-names>K</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Extensive aggregation of alpha-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site</article-title>. <source/>Acta Neuropathol Commun. (<year>2013</year>) <volume>1</volume>:<fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/2051-5960-1-12</pub-id><pub-id pub-id-type="pmid">24252552</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>MH</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Rather</surname><given-names>MI</given-names></name><name><surname>Bhat</surname><given-names>V</given-names></name><name><surname>Gopinath</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex</article-title>. <source/>PLoS ONE (<year>2016</year>) <volume>11</volume>:<fpage>e0155605</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0155605</pub-id><pub-id pub-id-type="pmid">27196560</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illingworth</surname><given-names>MA</given-names></name><name><surname>Meyer</surname><given-names>E</given-names></name><name><surname>Chong</surname><given-names>WK</given-names></name><name><surname>Manzur</surname><given-names>AY</given-names></name><name><surname>Carr</surname><given-names>LJ</given-names></name><name><surname>Younis</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>PLA2G6-associated neurodegeneration (PLAN): Further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease</article-title>. <source/>Mol Genet Metab. (<year>2014</year>) <volume>112</volume>:<fpage>183</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2014.03.008</pub-id><pub-id pub-id-type="pmid">24745848</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohani</surname><given-names>M</given-names></name><name><surname>Shahidi</surname><given-names>G</given-names></name><name><surname>Vali</surname><given-names>F</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Slow</surname><given-names>E</given-names></name><name><surname>Gahl</surname><given-names>WA</given-names></name><etal></etal></person-group>. <article-title>Oculogyric crises in PLA2G6 associated neurodegeneration</article-title>. <source/>Parkins Relat Disord. (<year>2018</year>) <volume>52</volume>:<fpage>111</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2018.03.010</pub-id><pub-id pub-id-type="pmid">29574084</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seitelberger</surname><given-names>F</given-names></name></person-group>. <article-title>Neuropathological conditions related to neuroaxonal dystrophy</article-title>. <source/>Acta Neuropathol. (<year>1971</year>) (<issue>Suppl. 5</issue>) <fpage>17</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="pmid">4103046</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>A</given-names></name><name><surname>Polster</surname><given-names>BJ</given-names></name><name><surname>Hayflick</surname><given-names>SJ</given-names></name></person-group>. <article-title>Clinical and genetic delineation of neurodegeneration with brain iron accumulation</article-title>. <source/>J Med Genet. (<year>2009</year>) <volume>46</volume>:<fpage>73</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2008.061929</pub-id><pub-id pub-id-type="pmid">18981035</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonelli</surname><given-names>A</given-names></name><name><surname>Romaniello</surname><given-names>R</given-names></name><name><surname>Grasso</surname><given-names>R</given-names></name><name><surname>Cavallini</surname><given-names>A</given-names></name><name><surname>Righini</surname><given-names>A</given-names></name><name><surname>Bresolin</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Novel splice-site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy</article-title>. <source/>Clin Genet. (<year>2010</year>) <volume>78</volume>:<fpage>432</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-0004.2010.01417.x</pub-id><pub-id pub-id-type="pmid">20584031</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salih</surname><given-names>MA</given-names></name><name><surname>Mundwiller</surname><given-names>E</given-names></name><name><surname>Khan</surname><given-names>AO</given-names></name><name><surname>Aldrees</surname><given-names>A</given-names></name><name><surname>Elmalik</surname><given-names>SA</given-names></name><name><surname>Hassan</surname><given-names>HH</given-names></name><etal></etal></person-group>. <article-title>New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations</article-title>. <source/>PLoS ONE (<year>2013</year>) <volume>8</volume>:<fpage>e76831</fpage>. <pub-id pub-id-type="doi">10.1371/annotation/cb01a74a-3330-4412-8040-2a94842420ed</pub-id><pub-id pub-id-type="pmid">24130795</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darling</surname><given-names>A</given-names></name><name><surname>Aguilera-Albesa</surname><given-names>S</given-names></name><name><surname>Tello</surname><given-names>CA</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name><name><surname>Tomas</surname><given-names>M</given-names></name><name><surname>Camino-Leon</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>PLA2G6-associated neurodegeneration: new insights into brain abnormalities and disease progression</article-title>. <source/>Parkinsonism Relat Disord (<year>2018</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2018.10.013</pub-id><pub-id pub-id-type="pmid">30340910</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gitiaux</surname><given-names>C</given-names></name><name><surname>Kaminska</surname><given-names>A</given-names></name><name><surname>Boddaert</surname><given-names>N</given-names></name><name><surname>Barcia</surname><given-names>G</given-names></name><name><surname>Gueden</surname><given-names>S</given-names></name><name><surname>The</surname><given-names>Tich SN</given-names></name><etal></etal></person-group>. <article-title>PLA2G6-associated neurodegeneration: Lessons from neurophysiological findings</article-title>. <source/>Eur J Paediatr Neurol. (<year>2018</year>) <volume>22</volume>:<fpage>854</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpn.2018.05.005</pub-id><pub-id pub-id-type="pmid">29859652</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardocci</surname><given-names>N</given-names></name><name><surname>Zorzi</surname><given-names>G</given-names></name><name><surname>Farina</surname><given-names>L</given-names></name><name><surname>Binelli</surname><given-names>S</given-names></name><name><surname>Scaioli</surname><given-names>W</given-names></name><name><surname>Ciano</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria</article-title>. <source/>Neurology (<year>1999</year>) <volume>52</volume>:<fpage>1472</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.52.7.1472</pub-id><pub-id pub-id-type="pmid">10227637</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crompton</surname><given-names>D</given-names></name><name><surname>Rehal</surname><given-names>PK</given-names></name><name><surname>Macpherson</surname><given-names>L</given-names></name><name><surname>Foster</surname><given-names>K</given-names></name><name><surname>Lunt</surname><given-names>P</given-names></name><name><surname>Hughes</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis</article-title>. <source/>Mol Genet Metab. (<year>2010</year>) <volume>100</volume>:<fpage>207</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2010.02.009</pub-id><pub-id pub-id-type="pmid">20226704</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davids</surname><given-names>M</given-names></name><name><surname>Kane</surname><given-names>MS</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Wolfe</surname><given-names>LA</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Raihan</surname><given-names>MA</given-names></name><etal></etal></person-group>. <article-title>Disruption of Golgi morphology and altered protein glycosylation in PLA2G6-associated neurodegeneration</article-title>. <source/>J Med Genet. (<year>2016</year>) <volume>53</volume>:<fpage>180</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103338</pub-id><pub-id pub-id-type="pmid">26668131</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Bao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Monozygotic twins with infantile neuroaxonal dystrophy: A case report and literature review</article-title>. <source/>Exp Ther Med. (<year>2016</year>) <volume>12</volume>:<fpage>3387</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2016.3761</pub-id><pub-id pub-id-type="pmid">27882168</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iannello</surname><given-names>G</given-names></name><name><surname>Graziano</surname><given-names>C</given-names></name><name><surname>Cenacchi</surname><given-names>G</given-names></name><name><surname>Cordelli</surname><given-names>DM</given-names></name><name><surname>Zuntini</surname><given-names>R</given-names></name><name><surname>Papa</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>A new PLA2G6 mutation in a family with infantile neuroaxonal dystrophy</article-title>. <source/>J Neurol Sci. (<year>2017</year>) <volume>381</volume>:<fpage>209</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2017.08.3260</pub-id><pub-id pub-id-type="pmid">28991683</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascalchi</surname><given-names>M</given-names></name><name><surname>Mari</surname><given-names>F</given-names></name><name><surname>Berti</surname><given-names>B</given-names></name><name><surname>Bartolini</surname><given-names>E</given-names></name><name><surname>Lenge</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Fast progression of cerebellar atrophy in pla2g6-associated infantile neuronal axonal dystrophy</article-title>. <source/>Cerebellum (<year>2017</year>) <volume>16</volume>:<fpage>742</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s12311-017-0843-z</pub-id><pub-id pub-id-type="pmid">28091863</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farina</surname><given-names>L</given-names></name><name><surname>Nardocci</surname><given-names>N</given-names></name><name><surname>Bruzzone</surname><given-names>MG</given-names></name><name><surname>D'incerti</surname><given-names>L</given-names></name><name><surname>Zorzi</surname><given-names>G</given-names></name><name><surname>Verga</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients</article-title>. <source/>Neuroradiology (<year>1999</year>) <volume>41</volume>:<fpage>376</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1007/s002340050768</pub-id><pub-id pub-id-type="pmid">10379598</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iodice</surname><given-names>A</given-names></name><name><surname>Spagnoli</surname><given-names>C</given-names></name><name><surname>Salerno</surname><given-names>GG</given-names></name><name><surname>Frattini</surname><given-names>D</given-names></name><name><surname>Bertani</surname><given-names>G</given-names></name><name><surname>Bergonzini</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Infantile neuroaxonal dystrophy and PLA2G6-associated neurodegeneration: an update for the diagnosis</article-title>. <source/>Brain Dev. (<year>2017</year>) <volume>39</volume>:<fpage>93</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2016.08.012</pub-id><pub-id pub-id-type="pmid">27884548</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy</article-title>. <source/>Eur J Neurol. (<year>2009</year>) <volume>16</volume>:<fpage>240</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02397.x</pub-id><pub-id pub-id-type="pmid">19138334</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardi</surname><given-names>B</given-names></name><name><surname>Pini</surname><given-names>A</given-names></name><name><surname>Santucci</surname><given-names>M</given-names></name><name><surname>Cenacchi</surname><given-names>C</given-names></name><name><surname>Garavaglia</surname><given-names>B</given-names></name><name><surname>Ucchino</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>MRI findings in patients with clinical onset consistent with Infantile Neuroaxonal Dystrophy (INAD), literature review, clinical and MRI Follow-up</article-title>. <source/>Neuroradiol J. (<year>2011</year>) <volume>24</volume>:<fpage>202</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1177/197140091102400207</pub-id><pub-id pub-id-type="pmid">24059609</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoun</surname><given-names>M</given-names></name><name><surname>Tiranti</surname><given-names>V</given-names></name></person-group>. <article-title>Mitochondria: A crossroads for lipid metabolism defect in neurodegeneration with brain iron accumulation diseases</article-title>. <source/>Int J Biochem Cell Biol. (<year>2015</year>) <volume>63</volume>:<fpage>25</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2015.01.018</pub-id><pub-id pub-id-type="pmid">25668476</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeh</surname><given-names>M</given-names></name></person-group>. <article-title>Neurodegeneration associated with genetic defects in phospholipase A2</article-title>. <source/>Neurology (<year>2009</year>) <volume>73</volume>:<fpage>819</fpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b2851b</pub-id><pub-id pub-id-type="pmid">19738181</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name><name><surname>Bhatia</surname><given-names>KP</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Hernandez</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><etal></etal></person-group>. <article-title>Characterization of PLA2G6 as a locus for dystonia-parkinsonism</article-title>. <source/>Ann Neurol. (<year>2009</year>) <volume>65</volume>:<fpage>19</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21415</pub-id><pub-id pub-id-type="pmid">18570303</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karkheiran</surname><given-names>S</given-names></name><name><surname>Shahidi</surname><given-names>GA</given-names></name><name><surname>Walker</surname><given-names>RH</given-names></name><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name></person-group>. <article-title>PLA2G6-associated dystonia-parkinsonism: case report and literature review</article-title>. <source/>Tremor Other Hyperkinet Mov. (<year>2015</year>) <volume>5</volume>:<fpage>317</fpage>. <pub-id pub-id-type="doi">10.7916/D84Q7T4W</pub-id><pub-id pub-id-type="pmid">26196026</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virmani</surname><given-names>T</given-names></name><name><surname>Thenganatt</surname><given-names>MA</given-names></name><name><surname>Goldman</surname><given-names>JS</given-names></name><name><surname>Kubisch</surname><given-names>C</given-names></name><name><surname>Greene</surname><given-names>PE</given-names></name><name><surname>Alcalay</surname><given-names>RN</given-names></name></person-group>. <article-title>Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia</article-title>. <source/>Parkinsonism Relat Disord. (<year>2014</year>) <volume>20</volume>:<fpage>245</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2013.10.016</pub-id><pub-id pub-id-type="pmid">24182522</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamel</surname><given-names>WA</given-names></name><name><surname>Al-Hashel</surname><given-names>JY</given-names></name><name><surname>Abdulsalam</surname><given-names>AJ</given-names></name><name><surname>Damier</surname><given-names>P</given-names></name><name><surname>Al-Mejalhem</surname><given-names>AY</given-names></name></person-group>. <article-title>PLA2G6-related parkinsonism presenting as adolescent behavior</article-title>. <source/>Acta Neurol Belg. (<year>2018</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1007/s13760-018-1003-z</pub-id><pub-id pub-id-type="pmid">30120687</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguti</surname><given-names>MC</given-names></name><name><surname>Melzi</surname><given-names>V</given-names></name><name><surname>Di</surname><given-names>Giacopo R</given-names></name><name><surname>Monfrini</surname><given-names>E</given-names></name><name><surname>Di</surname><given-names>Biase E</given-names></name><name><surname>Franco</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism</article-title>. <source/>Parkinsonism Relat Disord (<year>2015</year>) <volume>21</volume>:<fpage>337</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.01.001</pub-id><pub-id pub-id-type="pmid">25601130</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sina</surname><given-names>F</given-names></name><name><surname>Shojaee</surname><given-names>S</given-names></name><name><surname>Elahi</surname><given-names>E</given-names></name><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name></person-group>. <article-title>R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family</article-title>. <source/>Eur J Neurol. (<year>2009</year>) <volume>16</volume>:<fpage>101</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02356.x</pub-id><pub-id pub-id-type="pmid">19087156</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giri</surname><given-names>A</given-names></name><name><surname>Guven</surname><given-names>G</given-names></name><name><surname>Hanagasi</surname><given-names>H</given-names></name><name><surname>Hauser</surname><given-names>AK</given-names></name><name><surname>Erginul-Unaltuna</surname><given-names>N</given-names></name><name><surname>Bilgic</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>PLA2G6 Mutations Related to Distinct Phenotypes: A New Case with Early-onset Parkinsonism</article-title>. <source/>Tremor Other Hyperkinet Mov. (<year>2016</year>) <volume>6</volume>:<fpage>363</fpage>. <pub-id pub-id-type="doi">10.7916/D81G0M12</pub-id><pub-id pub-id-type="pmid">27127721</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomiyama</surname><given-names>H</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Ogaki</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yamashita</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>PLA2G6 variant in Parkinson's disease</article-title>. <source/>J Hum Genet. (<year>2011</year>) <volume>56</volume>:<fpage>401</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/jhg.2011.22</pub-id><pub-id pub-id-type="pmid">21368765</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Association between PLA2G6 gene polymorphisms and Parkinson's disease in the Chinese Han population</article-title>. <source/>Parkinsonism Relat Disord. (<year>2012</year>) <volume>18</volume>:<fpage>641</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2012.02.015</pub-id><pub-id pub-id-type="pmid">22459563</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>JY</given-names></name><name><surname>Tang</surname><given-names>BS</given-names></name><name><surname>Shi</surname><given-names>CH</given-names></name><name><surname>Lv</surname><given-names>ZY</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>RL</given-names></name><etal></etal></person-group>. <article-title>Analysis of PLA2G6 gene mutation in sporadic early-onset parkinsonism patients from Chinese population</article-title>. <source/>Neurosci Lett. (<year>2012</year>) <volume>514</volume>:<fpage>156</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2012.02.078</pub-id><pub-id pub-id-type="pmid">22406380</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozes</surname><given-names>B</given-names></name><name><surname>Karagoz</surname><given-names>N</given-names></name><name><surname>Schule</surname><given-names>R</given-names></name><name><surname>Rebelo</surname><given-names>A</given-names></name><name><surname>Sobrido</surname><given-names>MJ</given-names></name><name><surname>Harmuth</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia</article-title>. <source/>Clin Genet. (<year>2017</year>) <volume>92</volume>:<fpage>534</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/cge.13008</pub-id><pub-id pub-id-type="pmid">28295203</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>K</given-names></name><name><surname>Ichinose</surname><given-names>Y</given-names></name><name><surname>Ishiura</surname><given-names>H</given-names></name><name><surname>Nan</surname><given-names>H</given-names></name><name><surname>Mitsui</surname><given-names>J</given-names></name><name><surname>Takahashi</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>PLA2G6-associated neurodegeneration presenting as a complicated form of hereditary spastic paraplegia</article-title>. <source/>J Hum Genet. (<year>2018</year>) [Epub ahead of print]. <pub-id pub-id-type="doi">10.1038/s10038-018-0519-7.</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Dong</surname><given-names>HL</given-names></name><name><surname>Li</surname><given-names>LX</given-names></name><name><surname>Ni</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>HF</given-names></name><etal></etal></person-group>. <article-title>Novel PLA2G6 mutations and clinical heterogeneity in Chinese cases with phospholipase A2-associated neurodegeneration</article-title>. <source/>Parkinsonism Relat Disord. (<year>2018</year>) <volume>49</volume>:<fpage>88</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2018.02.010</pub-id><pub-id pub-id-type="pmid">29454663</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EK</given-names></name><name><surname>Ho</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Prakash</surname><given-names>KM</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group>. <article-title>PLA2G6 mutations and Parkinson's disease</article-title>. <source/>Ann Neurol. (<year>2010</year>) <volume>67</volume>:<fpage>148</fpage>. <pub-id pub-id-type="doi">10.1002/ana.21663</pub-id><pub-id pub-id-type="pmid">20186954</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Tomiyama</surname><given-names>H</given-names></name><name><surname>Tachibana</surname><given-names>N</given-names></name><name><surname>Ogaki</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Funayama</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism</article-title>. <source/>Neurology (<year>2010</year>) <volume>75</volume>:<fpage>1356</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f73649</pub-id><pub-id pub-id-type="pmid">20938027</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kauther</surname><given-names>KM</given-names></name><name><surname>Hoft</surname><given-names>C</given-names></name><name><surname>Rissling</surname><given-names>I</given-names></name><name><surname>Oertel</surname><given-names>WH</given-names></name><name><surname>Moller</surname><given-names>JC</given-names></name></person-group>. <article-title>The PLA2G6 gene in early-onset Parkinson's disease</article-title>. <source/>Mov Disord. (<year>2011</year>) <volume>26</volume>:<fpage>2415</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/mds.23851</pub-id><pub-id pub-id-type="pmid">21812034</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>P</given-names></name><name><surname>Hogarth</surname><given-names>P</given-names></name><name><surname>Hayflick</surname><given-names>S</given-names></name><name><surname>Macleod</surname><given-names>P</given-names></name><name><surname>Kuriakose</surname><given-names>R</given-names></name><name><surname>Mckenzie</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism</article-title>. <source/>Mov Disord. (<year>2012</year>) <volume>27</volume>:<fpage>1698</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/mds.25160</pub-id><pub-id pub-id-type="pmid">23192926</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>CS</given-names></name><name><surname>Lai</surname><given-names>SC</given-names></name><name><surname>Wu</surname><given-names>RM</given-names></name><name><surname>Weng</surname><given-names>YH</given-names></name><name><surname>Huang</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>RS</given-names></name><etal></etal></person-group>. <article-title>PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease</article-title>. <source/>Am J Med Genet B Neuropsychiatr Genet. (<year>2012</year>) 159B:183–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.32012</pub-id><pub-id pub-id-type="pmid">22213678</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koroglu</surname><given-names>C</given-names></name><name><surname>Seven</surname><given-names>M</given-names></name><name><surname>Tolun</surname><given-names>A</given-names></name></person-group>. <article-title>Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism</article-title>. <source/>J Med Genet. (<year>2013</year>) <volume>50</volume>:<fpage>515</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2013-101634</pub-id><pub-id pub-id-type="pmid">23749988</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Follow-up study of 25 Chinese children with PLA2G6-associated neurodegeneration</article-title>. <source/>Eur J Neurol. (<year>2013</year>) <volume>20</volume>:<fpage>322</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-1331.2012.03856.x</pub-id><pub-id pub-id-type="pmid">22934738</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>M</given-names></name><name><surname>Bijarnia-Mahay</surname><given-names>S</given-names></name><name><surname>Kingsmore</surname><given-names>S</given-names></name><name><surname>Farrow</surname><given-names>E</given-names></name><name><surname>Saunders</surname><given-names>C</given-names></name><name><surname>Saxena</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Molecular diagnosis of infantile neuro axonal dystrophy by next generation sequencing</article-title>. <source/>Indian J Pediatr. (<year>2015</year>) <volume>82</volume>:<fpage>474</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s12098-014-1608-z</pub-id><pub-id pub-id-type="pmid">25348461</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Maawali</surname><given-names>A</given-names></name><name><surname>Yoon</surname><given-names>G</given-names></name><name><surname>Feigenbaum</surname><given-names>AS</given-names></name><name><surname>Halliday</surname><given-names>WC</given-names></name><name><surname>Clarke</surname><given-names>JT</given-names></name><name><surname>Branson</surname><given-names>HM</given-names></name><etal></etal></person-group>. <article-title>Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis</article-title>. <source/>Neuroradiology (<year>2016</year>) <volume>58</volume>:<fpage>1035</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1007/s00234-016-1726-6</pub-id><pub-id pub-id-type="pmid">27516098</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blake</surname><given-names>RB</given-names></name><name><surname>Gilbert</surname><given-names>DL</given-names></name><name><surname>Schapiro</surname><given-names>MB</given-names></name></person-group>. <article-title>Child neurology: two sisters with dystonia and regression: PLA2G6-associated neurodegeneration</article-title>. <source/>Neurology (<year>2016</year>) <volume>87</volume>:<fpage>e1</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000002804</pub-id><pub-id pub-id-type="pmid">27378808</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dastsooz</surname><given-names>H</given-names></name><name><surname>Nemati</surname><given-names>H</given-names></name><name><surname>Fard</surname><given-names>MAF</given-names></name><name><surname>Fardaei</surname><given-names>M</given-names></name><name><surname>Faghihi</surname><given-names>MA</given-names></name></person-group>. <article-title>Novel mutations in PANK2 and PLA2G6 genes in patients with neurodegenerative disorders: two case reports</article-title>. <source/>BMC Med Genet. (<year>2017</year>) <volume>18</volume>:<fpage>87</fpage>. <pub-id pub-id-type="doi">10.1186/s12881-017-0439-y</pub-id><pub-id pub-id-type="pmid">28821231</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Identification of novel compound mutations in pla2g6-associated neurodegeneration patient with characteristic MRI Imaging</article-title>. <source/>Mol Neurobiol. (<year>2017</year>) <volume>54</volume>:<fpage>4636</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-9991-2</pub-id><pub-id pub-id-type="pmid">27395053</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelis</surname><given-names>JP</given-names></name><name><surname>Hattingen</surname><given-names>E</given-names></name><name><surname>Gaertner</surname><given-names>FC</given-names></name><name><surname>Minnerop</surname><given-names>M</given-names></name><name><surname>Traber</surname><given-names>F</given-names></name><name><surname>Biskup</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Expanded phenotype and hippocampal involvement in a novel compound heterozygosity of adult PLA2G6 associated neurodegeneration (PARK14)</article-title>. <source/>Parkinsonism Relat Disord. (<year>2017</year>) <volume>37</volume>:<fpage>111</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.01.005</pub-id><pub-id pub-id-type="pmid">28094106</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirth</surname><given-names>T</given-names></name><name><surname>Weibel</surname><given-names>S</given-names></name><name><surname>Montaut</surname><given-names>S</given-names></name><name><surname>Bigaut</surname><given-names>K</given-names></name><name><surname>Rudolf</surname><given-names>G</given-names></name><name><surname>Chelly</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Severe early-onset impulsive compulsive behavior and psychosis in PLA2G6-related juvenile Parkinson's disease</article-title>. <source/>Parkinsonism Relat Disord. (<year>2017</year>) <volume>41</volume>:<fpage>127</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.05.014</pub-id><pub-id pub-id-type="pmid">28549837</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>C</given-names></name><name><surname>Funayama</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Seino</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Mutation screening of PLA2G6 in Japanese patients with early onset dystonia-parkinsonism</article-title>. <source/>J Neural Transm. (<year>2017</year>) <volume>124</volume>:<fpage>431</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-016-1658-7</pub-id><pub-id pub-id-type="pmid">27942883</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsayed</surname><given-names>LEO</given-names></name><name><surname>Mohammed</surname><given-names>IN</given-names></name><name><surname>Hamed</surname><given-names>A</given-names></name><name><surname>Elseed</surname><given-names>MA</given-names></name><name><surname>Salih</surname><given-names>MM</given-names></name><name><surname>Yahia</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Case report of a novel homozygous splice site mutation in PLA2G6 gene causing infantile neuroaxonal dystrophy in a Sudanese family</article-title>. <source/>BMC Med Genet. (<year>2018</year>) <volume>19</volume>:<fpage>72</fpage>. <pub-id pub-id-type="doi">10.1186/s12881-018-0592-y</pub-id><pub-id pub-id-type="pmid">29739362</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferese</surname><given-names>R</given-names></name><name><surname>Scala</surname><given-names>S</given-names></name><name><surname>Biagioni</surname><given-names>F</given-names></name><name><surname>Giardina</surname><given-names>E</given-names></name><name><surname>Zampatti</surname><given-names>S</given-names></name><name><surname>Modugno</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Heterozygous PLA2G6 mutation leads to iron accumulation within basal ganglia and Parkinson's disease</article-title>. <source/>Front Neurol. (<year>2018</year>) <volume>9</volume>:<fpage>536</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2018.00536</pub-id><pub-id pub-id-type="pmid">30042723</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>T</given-names></name><name><surname>Pu</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>HY</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Si</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Genetic analysis of ATP13A2, PLA2G6 and FBXO7 in a cohort of Chinese patients with early-onset Parkinson's disease</article-title>. <source/>Sci Rep. (<year>2018</year>) <volume>8</volume>:<fpage>14028</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-32217-4</pub-id><pub-id pub-id-type="pmid">30232368</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wu Tang</surname><given-names>J</given-names></name></person-group>. <article-title>Infantile neuroaxonal dystrophy caused by PLA2G6 gene mutation in a Chinese patient: a case report</article-title>. <source/>Exp Ther Med. (<year>2018</year>) <volume>16</volume>:<fpage>1290</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2018.6347</pub-id><pub-id pub-id-type="pmid">30112060</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malley</surname><given-names>KR</given-names></name><name><surname>Koroleva</surname><given-names>O</given-names></name><name><surname>Miller</surname><given-names>I</given-names></name><name><surname>Sanishvili</surname><given-names>R</given-names></name><name><surname>Jenkins</surname><given-names>CM</given-names></name><name><surname>Gross</surname><given-names>RW</given-names></name><etal></etal></person-group>. <article-title>The structure of iPLA2beta reveals dimeric active sites and suggests mechanisms of regulation and localization</article-title>. <source/>Nat Commun. (<year>2018</year>) <volume>9</volume>:<fpage>765</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-03193-0</pub-id><pub-id pub-id-type="pmid">29472584</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Nowatzke</surname><given-names>W</given-names></name><name><surname>Ramanadham</surname><given-names>S</given-names></name><name><surname>Turk</surname><given-names>J</given-names></name></person-group>. <article-title>Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1</article-title>. <source/>J Biol Chem. (<year>1999</year>) <volume>274</volume>:<fpage>9607</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.14.9607</pub-id><pub-id pub-id-type="pmid">10092647</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooks</surname><given-names>SB</given-names></name><name><surname>Cummings</surname><given-names>BS</given-names></name></person-group>. <article-title>Role of Ca2+-independent phospholipase A2 in cell growth and signaling</article-title>. <source/>Biochem Pharmacol. (<year>2008</year>) <volume>76</volume>:<fpage>1059</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2008.07.044</pub-id><pub-id pub-id-type="pmid">18775417</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>EJ</given-names></name><name><surname>Kempner</surname><given-names>ES</given-names></name><name><surname>Dennis</surname><given-names>EA</given-names></name></person-group>. <article-title>Ca(2+)-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization</article-title>. <source/>J Biol Chem. (<year>1994</year>) <volume>269</volume>:<fpage>9227</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="pmid">8132660</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Kriz</surname><given-names>RW</given-names></name><name><surname>Wolfman</surname><given-names>N</given-names></name><name><surname>Shaffer</surname><given-names>M</given-names></name><name><surname>Seehra</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>SS</given-names></name></person-group>. <article-title>A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs</article-title>. <source/>J Biol Chem. (<year>1997</year>) <volume>272</volume>:<fpage>8567</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.13.8567</pub-id><pub-id pub-id-type="pmid">9079687</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balsinde</surname><given-names>J</given-names></name><name><surname>Balboa</surname><given-names>MA</given-names></name></person-group>. <article-title>Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells</article-title>. <source/>Cell Signal. (<year>2005</year>) <volume>17</volume>:<fpage>1052</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2005.03.002</pub-id><pub-id pub-id-type="pmid">15993747</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farooqui</surname><given-names>AA</given-names></name><name><surname>Horrocks</surname><given-names>LA</given-names></name></person-group>
<article-title>Brain phospholipases A2: a perspective on the history</article-title>. <source/>Prostaglandins Leukot Essent Fatty Acids (<year>2004</year>) <volume>71</volume>:<fpage>161</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2004.03.004</pub-id><pub-id pub-id-type="pmid">15253885</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name></person-group>. <article-title>Specific differential expression of phospholipase A2 subtypes in rat cerebellum</article-title>. <source/>J Neurocytol. (<year>2004</year>) <volume>33</volume>:<fpage>297</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1023/B:NEUR.0000044191.83858.f7</pub-id><pub-id pub-id-type="pmid">15475685</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farooqui</surname><given-names>AA</given-names></name><name><surname>Ong</surname><given-names>WY</given-names></name><name><surname>Horrocks</surname><given-names>LA</given-names></name></person-group>. <article-title>Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders</article-title>. <source/>Pharmacol Rev. (<year>2006</year>) <volume>58</volume>:<fpage>591</fpage>–<lpage>620</lpage>. <pub-id pub-id-type="doi">10.1124/pr.58.3.7</pub-id><pub-id pub-id-type="pmid">16968951</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calandria</surname><given-names>JM</given-names></name><name><surname>Bazan</surname><given-names>NG</given-names></name></person-group>. <article-title>Neuroprotectin D1 modulates the induction of pro-inflammatory signaling and promotes retinal pigment epithelial cell survival during oxidative stress</article-title>. <source/>Adv Exp Med Biol. (<year>2010</year>) <volume>664</volume>:<fpage>663</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4419-1399-9_76</pub-id><pub-id pub-id-type="pmid">20238071</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>GY</given-names></name><name><surname>Simonyi</surname><given-names>A</given-names></name><name><surname>Fritsche</surname><given-names>KL</given-names></name><name><surname>Chuang</surname><given-names>DY</given-names></name><name><surname>Hannink</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases</article-title>. <source/>Prostaglandins Leukot Essent Fatty Acids (<year>2018</year>) <volume>136</volume>:<fpage>3</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2017.03.006</pub-id><pub-id pub-id-type="pmid">28314621</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cámara-Lemarroy</surname><given-names>CR</given-names></name><name><surname>Guzmán-De</surname><given-names>La Garza FJ</given-names></name><name><surname>Fernández-Garza</surname><given-names>NE</given-names></name></person-group>. <article-title>Molecular inflammatory mediators in peripheral nerve degeneration and regeneration</article-title>. <source/>Neuroimmunomodulation (<year>2010</year>) <volume>17</volume>:<fpage>314</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1159/000292020</pub-id><pub-id pub-id-type="pmid">20407283</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broersen</surname><given-names>K</given-names></name><name><surname>Ruiperez</surname><given-names>V</given-names></name><name><surname>Davletov</surname><given-names>B</given-names></name></person-group>. <article-title>Structural and aggregation properties of alpha-synuclein linked to phospholipase A2 Action</article-title>. <source/>Protein Pept Lett. (<year>2018</year>) <volume>25</volume>:<fpage>368</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.2174/0929866525666180326120052</pub-id><pub-id pub-id-type="pmid">29577851</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>I</given-names></name><name><surname>Turk</surname><given-names>J</given-names></name><name><surname>Mancuso</surname><given-names>DJ</given-names></name><name><surname>Montier</surname><given-names>L</given-names></name><name><surname>Wohltmann</surname><given-names>M</given-names></name><name><surname>Wozniak</surname><given-names>DF</given-names></name><etal></etal></person-group>. <article-title>Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations</article-title>. <source/>Am J Pathol. (<year>2008</year>) <volume>172</volume>:<fpage>406</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2008.070823</pub-id><pub-id pub-id-type="pmid">18202189</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adibhatla</surname><given-names>RM</given-names></name><name><surname>Hatcher</surname><given-names>JF</given-names></name></person-group>. <article-title>Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities</article-title>. <source/>Antioxid Redox Signal. (<year>2010</year>) <volume>12</volume>:<fpage>125</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2009.2668</pub-id><pub-id pub-id-type="pmid">19624272</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinghorn</surname><given-names>KJ</given-names></name><name><surname>Castillo-Quan</surname><given-names>JI</given-names></name><name><surname>Bartolome</surname><given-names>F</given-names></name><name><surname>Angelova</surname><given-names>PR</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Pope</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction</article-title>. <source/>Brain (<year>2015</year>) <volume>138</volume>:<fpage>1801</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awv132</pub-id><pub-id pub-id-type="pmid">26001724</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>PT</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Mao</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>KL</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to alpha-Synuclein Gain</article-title>. <source/>Cell Metab. (<year>2018</year>) <volume>28</volume>:<fpage>605</fpage>–<lpage>618</lpage>.e606. <pub-id pub-id-type="doi">10.1016/j.cmet.2018.05.019</pub-id><pub-id pub-id-type="pmid">29909971</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliadi</surname><given-names>KG</given-names></name><name><surname>Gluscencova</surname><given-names>OB</given-names></name><name><surname>Iliadi</surname><given-names>N</given-names></name><name><surname>Boulianne</surname><given-names>GL</given-names></name></person-group>. <article-title>Mutations in the Drosophila homolog of human PLA2G6 give rise to age-dependent loss of psychomotor activity and neurodegeneration</article-title>. <source/>Sci Rep. (<year>2018</year>) <volume>8</volume>:<fpage>2939</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-21343-8</pub-id><pub-id pub-id-type="pmid">29440694</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Azcona</surname><given-names>LJ</given-names></name><name><surname>Paisan-Ruiz</surname><given-names>C</given-names></name></person-group>. <article-title>Pla2g6 deficiency in zebrafish leads to dopaminergic cell death, axonal degeneration, increased beta-synuclein expression, and defects in brain functions and pathways</article-title>. <source/>Mol Neurobiol. (<year>2018</year>) <volume>55</volume>:<fpage>6734</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-017-0846-2</pub-id><pub-id pub-id-type="pmid">29344929</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>C-C</given-names></name><name><surname>Lu</surname><given-names>C-S</given-names></name><name><surname>Weng</surname><given-names>Y-H</given-names></name><name><surname>Chen</surname><given-names>Y-L</given-names></name><name><surname>Huang</surname><given-names>Y-Z</given-names></name><name><surname>Chen</surname><given-names>R-S</given-names></name><etal></etal></person-group>. <article-title>PARK14 (D331Y) PLA2G6 causes early-onset degeneration of substantia nigra dopaminergic neurons by inducing mitochondrial dysfunction, ER stress, mitophagy impairment and transcriptional dysregulation in a knockin mouse model</article-title>. <source/>Mol Neurobiol. (<year>2018</year>) <pub-id pub-id-type="doi">10.1007/s12035-018-1118-5.</pub-id> [Epub ahead of print]. <pub-id pub-id-type="pmid">30088174</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strokin</surname><given-names>M</given-names></name><name><surname>Reiser</surname><given-names>G</given-names></name></person-group>
<article-title>Neurons and astrocytes in an infantile neuroaxonal dystrophy (INAD) mouse model show characteristic alterations in glutamate-induced Ca(2+) signaling</article-title>. <source/>Neurochem Int. (<year>2017</year>) <volume>108</volume>:<fpage>121</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2017.03.004</pub-id><pub-id pub-id-type="pmid">28279750</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>GY</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>MD</given-names></name><name><surname>Simonyi</surname><given-names>A</given-names></name></person-group>. <article-title>Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases</article-title>. <source/>J Lipid Res. (<year>2004</year>) <volume>45</volume>:<fpage>205</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.R300016-JLR200</pub-id><pub-id pub-id-type="pmid">14657205</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Vales</surname><given-names>R</given-names></name><name><surname>Ghasemlou</surname><given-names>N</given-names></name><name><surname>Redensek</surname><given-names>A</given-names></name><name><surname>Kerr</surname><given-names>BJ</given-names></name><name><surname>Barbayianni</surname><given-names>E</given-names></name><name><surname>Antonopoulou</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Phospholipase A2 superfamily members play divergent roles after spinal cord injury</article-title>. <source/>FASEB J. (<year>2011</year>) <volume>25</volume>:<fpage>4240</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1096/fj.11-183186</pub-id><pub-id pub-id-type="pmid">21868473</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palavicini</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Hosang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Tomiyama</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A2 in a spatial-specific manner</article-title>. <source/>Acta Neuropathol Commun. (<year>2017</year>) <volume>5</volume>:<fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/s40478-017-0460-6</pub-id><pub-id pub-id-type="pmid">28750656</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>LA</given-names></name><name><surname>Jing</surname><given-names>Z</given-names></name><name><surname>O'brien</surname><given-names>DE</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Kotzbauer</surname><given-names>PT</given-names></name></person-group>
<article-title>Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism</article-title>. <source/>PLoS ONE (<year>2010</year>) <volume>5</volume>:<fpage>e12897</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0012897</pub-id><pub-id pub-id-type="pmid">20886109</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Löchte</surname><given-names>T</given-names></name><name><surname>Delamonte</surname><given-names>SM</given-names></name><name><surname>Braenne</surname><given-names>I</given-names></name><name><surname>Hicks</surname><given-names>AA</given-names></name><name><surname>Zschiedrich-Jansen</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>PLA2G6mutations and Parkinsonism: long-term follow-up of clinical features and neuropathology</article-title>. <source/>Mov Disord. (<year>2016</year>) <volume>31</volume>:<fpage>1927</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/mds.26814</pub-id><pub-id pub-id-type="pmid">27709683</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>LK</given-names></name><name><surname>Valentine</surname><given-names>CJ</given-names></name><name><surname>Keim</surname><given-names>SA</given-names></name></person-group>. <article-title>DHA supplementation: current implications in pregnancy and childhood</article-title>. <source/>Pharmacol Res. (<year>2013</year>) <volume>70</volume>:<fpage>13</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2012.12.003</pub-id><pub-id pub-id-type="pmid">23266567</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>